Frequency Therapeutics Inc (KRRO) stock has hit a 52-week low, trading at $29.8, marking a significant downturn for the company within the past year. According to InvestingPro data, the company maintains a FAIR financial health score, with analysts setting price targets between $105 and $180. This latest price level reflects a stark contrast to the stock’s performance over the last 12 months, with Frequency Therapeutics Inc experiencing a substantial 1-year change, plummeting by -44.71%. Despite the decline, the company holds more cash than debt and maintains a strong current ratio of 11.23, indicating solid short-term liquidity. Investors are closely monitoring the stock as it navigates through this challenging period, with the 52-week low serving as a critical point of reference for the company’s valuation on the market. InvestingPro subscribers have access to 12 additional investment tips and a comprehensive Pro Research Report for deeper analysis of KRRO’s potential.
In other recent news, Korro Bio has drawn the attention of Jones Trading, which initiated coverage on the company with a Buy rating and a $130 price target. Jones Trading highlighted Korro Bio’s focus on RNA editing and its leading program, KRRO-110, which targets alpha-1 antitrypsin deficiency (AATD), a rare pulmonary disease affecting approximately 70,000 patients in the U.S. The firm’s confidence in Korro Bio’s technology, particularly the use of ADAR to modify proteins in vivo, was emphasized.
Jones Trading anticipates initial data from the Phase 1/2a study of KRRO-110 in the second half of 2025. Additionally, they view Korro Bio’s recent partnership with Novo Nordisk (NYSE:NVO) for cardiometabolic diseases as an indication of potential larger deals due to the pharmaceutical industry’s interest in RNA editing technologies. These recent developments underscore Korro Bio’s potential in the biotechnology sector and its innovative approach to RNA editing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.